相关实验视频

Updated: Aug 2, 2026

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology

Published on: March 24, 2015

瘤培养血小板中的FLNA基因可用于识别NSCLC高风险人群

Ruiling Zu¹, Hanxiao Ren², Xing Yin¹

¹Department of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of the University of Electronic Science and Technology of China, Chengdu, China.

Journal of cellular and molecular medicine

|April 10, 2025

概括

血小板RNA测序确定FLNA是非小细胞肺癌 (NSCLC) 的潜在生物标志物. 血小板中FLNA水平升高可能表明NSCLC发病率,转移和较差的存活率,有助于风险评估.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物标志物发现发现

背景情况:

选择性查非小细胞肺癌 (NSCLC) 风险至关重要,以尽量减少过度诊断和过度治疗.
血小板及其组成部分在临床环境中为NSCLC风险评估提供了可访问的液体活检标志物的潜力.

研究的目的:

从血小板RNA测序数据集中识别特定的基因,以区分NSCLC患者与健康的捐赠者以及良性结节患者.
在临床试验中验证选定基因的表达,并评估它们在NSCLC转移和生存方面的预后价值.

主要方法:

对血小板RNA测序数据集 (GSE) 的分析,以确定NSCLC患者和健康捐赠者之间差异表达的基因.
在临床试验中验证基因表达,使用接收器操作特征 (ROC) 曲线评估诊断准确性.
评估基因表达水平与NSCLC转移和患者存活率之间的关联.

主要成果:

与健康捐赠者和患有良性结节的患者相比,NSCLC患者的血小板中FLNA基因的mRNA表达显著更高.
FLNA证明了诊断潜力,曲线下的面积 (AUC) 为0.716,用于区分NSCLC与健康个体,以及区分良性疾病的0.705.
在区分转移性NSCLC与非转移性NSCLC方面,FLNA显示了0.595的中度AUC,高FLNA表达与较差的长期存活相关.

结论:

血小板衍生的细胞外囊泡 (TEP) 中FLNA表达升高可能作为NSCLC发病率和转移的潜在生物标志物.
作为NSCLC高风险估计的生物标志物,FLNA具有前景,有可能改善患者分层和管理.

关键词:

在这里,FLNA FLNA FLNA.在NSCLCLC中,我们可以看到.生物标志物生物标志物癌症查癌症查液体活检活检液体活检瘤形成的血小板.

更多相关视频

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...